AstraZeneca may have had a rough ride following a safety scare with its COVID-19 vaccine, but the company’s busy pipeline is producing successes in other areas.
AstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US cancer experts reviewing long-term trial data.
AstraZeneca and Merck & Co have hit back at their rival GlaxoSmithKline after the FDA allowed Lynparza to be used in a wider group of ovarian cancer patients when combined with Roche’s
The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class
GSK looks like it is starting to show the benefit of a revamp of its business under chief executive Emma Walmsley, with recent product launches driving a 10% rise in sales
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.